Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte wins special advanced-therapy designation for ATEV
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Humacyte, Inc. (HUMA) reachead $5.17 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.
2 Stocks Under $20 Making Outsized Moves
This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks that are soaring today: Humacyte Inc (NYSE:HUMA) and American Semiconductor Corp (NASDAQ:AMSC).
Humacyte (HUMA) stock price is pumping but 1 key risk remain
Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021.
This stock surged 100% since US Senator bought it 2 months ago
While Nancy Pelosi often dominates discussions on insider trades in the US, the year 2024 has seen a shift in focus to her Republican counterpart, Tommy Tuberville. His series of trades, particularly notable for their insider nature, have sparked significant interest.
